Holen Sie sich die Stockscreener-App
2.02
0.49%
-0.010
Schlusskurs vom Vortag:
$2.03
Offen:
$2.05
24-Stunden-Volumen:
54,591
Relative Volume:
0.36
Marktkapitalisierung:
$25.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.48%
1M Leistung:
-19.20%
6M Leistung:
-62.94%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.93
$2.09
1-Wochen-Bereich:
$1.91
$2.23
52-Wochen-Spanne:
$1.70
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Firmenname
Onkure Therapeutics Inc
Sektor
Branche
Telefon
(720) 307-2892
Adresse
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Vergleichen Sie OKUR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.02 | 27.56M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
386.57 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.05 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.92 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
639.12 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.00 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-30 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-05 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-10 | Eingeleitet | Oppenheimer | Outperform |
| 2023-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-12-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Eingeleitet | William Blair | Outperform |
| 2023-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-03 | Eingeleitet | BofA Securities | Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-22 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Onkure Therapeutics Inc Aktie (OKUR) Neueste Nachrichten
Will OnKure Therapeutics Inc. stock recover after recent dropStock Holding Strategy Long-Term Summary Sheet - Newser
How sentiment analysis helps forecast OnKure Therapeutics Inc.Free Access to Real-Time Trade Insights - Newser
How to monitor OnKure Therapeutics Inc. with trend dashboardsLow Risk High Confidence Watchlist Builder - Newser
Applying big data sentiment scoring on OnKure Therapeutics Inc.Daily Investment Ideas with Market Insight - Newser
Price momentum metrics for OnKure Therapeutics Inc. explainedLong-Term Safety Investment Analysis Report - Newser
OnKure Therapeutics Inc. stock outlook for YEARReal Time Growth Signal with Smart Setup - Newser
What makes OnKure Therapeutics Inc. stock price move sharplyShort-Term AI-Based Stock Price Forecast - Newser
OnKure Therapeutics (OKUR) to Release Earnings on Tuesday - Defense World
Is OnKure Therapeutics Inc. Stock a Good Fit for Conservative InvestorsDay Trading Setup Forecast with Trend Model - Newser
OnKure Therapeutics Inc. stock trend forecastQuarterly Investment Outlook and Key Summary - Newser
Using data models to predict OnKure Therapeutics Inc. stock movementFree Buy Low Sell High Stock Watch - Newser
Using data filters to optimize entry into OnKure Therapeutics Inc.Entry Zone Watchlist With Momentum Focus - Newser
Why OnKure Therapeutics Inc. stock attracts strong analyst attentionFree Scalable Portfolio Growth Suggestions - Newser
How many analysts rate OnKure Therapeutics Inc. as a “Buy”Get ahead with breakthrough trading ideas - Jammu Links News
What is OnKure Therapeutics Inc. company’s growth strategyFree Buy/Sell Signal Notifications - Jammu Links News
What drives OnKure Therapeutics Inc. stock pricePhenomenal capital gains - Jammu Links News
How strong is OnKure Therapeutics Inc. company’s balance sheetCapitalize on emerging growth stocks - Jammu Links News
What is the risk reward ratio of investing in OnKure Therapeutics Inc. stockUnlock powerful trading signals for profits - Jammu Links News
When is OnKure Therapeutics Inc. stock expected to show significant growthHigh-profit stock alerts - Jammu Links News
Is OnKure Therapeutics Inc. a good long term investmentInvest smarter with daily stock recommendations - Jammu Links News
What are the technical indicators suggesting about OnKure Therapeutics Inc.Capitalize on market shifts before others do - Jammu Links News
How does OnKure Therapeutics Inc. generate profit in a changing economyCapitalize on emerging market sectors - Jammu Links News
Why is OnKure Therapeutics Inc. stock attracting strong analyst attentionAchieve impressive returns with smart timing - Jammu Links News
How to use a screener to detect OnKure Therapeutics Inc. breakoutsIn-Depth Stock Trading Volume Analysis - Newser
Finanzdaten der Onkure Therapeutics Inc-Aktie (OKUR)
Es liegen keine Finanzdaten für Onkure Therapeutics Inc (OKUR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Onkure Therapeutics Inc-Aktie (OKUR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Jun 23 '25 |
Sale |
2.38 |
303 |
722 |
12,906 |
| Cormorant Asset Management, LP | Former 10% Owner |
May 15 '25 |
Sale |
1.85 |
1,813,439 |
3,363,023 |
0 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
1,129,730 |
2,090,000 |
1,129,730 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
270,270 |
500,000 |
1,709,944 |
| Cormorant Asset Management, LP | 10% Owner |
May 12 '25 |
Sale |
1.99 |
24,300 |
48,236 |
1,813,439 |
| Saccomano Nicholas A | President and CEO |
Apr 07 '25 |
Sale |
2.67 |
516 |
1,378 |
3,682 |
| Saccomano Nicholas A | President and CEO |
Apr 04 '25 |
Sale |
3.33 |
358 |
1,191 |
4,198 |
| Leverone Jason A. | Chief Financial Officer |
Apr 07 '25 |
Sale |
2.67 |
1,844 |
4,925 |
13,209 |
| Leverone Jason A. | Chief Financial Officer |
Apr 04 '25 |
Sale |
3.33 |
1,278 |
4,253 |
15,053 |
| Leonard Braden Michael | 10% Owner |
Sep 25 '24 |
Buy |
1.50 |
68,746 |
102,872 |
3,457,395 |
0.94%
2.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):